{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:17:45Z","timestamp":1790047065487,"version":"4.0.1"},"reference-count":82,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Acute myeloid leukemia (AML) is an aggressive malignancy, and many elderly\/unfit patients cannot receive intensive and potentially curative therapy. These patients receive low-toxicity disease-stabilizing treatment. The combination of all-trans retinoic acid (ATRA) and the histone deacetylase inhibitor valproic acid can stabilize the disease for a subset of such patients. We performed untargeted serum metabolomic profiling for 44 AML patients receiving treatment based on ATRA and valproic acid combined with low-dose cytotoxic drugs (cytarabine, hydroxyurea, 6-mercaptopurin) which identified 886 metabolites. When comparing pretreatment samples from responders and non-responders, metabolites mainly belonging to amino acid and lipid (i.e., fatty acid) pathways were altered. Furthermore, patients with rapidly progressive disease showed an extensively altered lipid metabolism. Both ATRA and valproic acid monotherapy also altered the amino acid and lipid metabolite profiles; however, these changes were only highly significant for valproic acid treatment. Twenty-three metabolites were significantly altered by seven-day valproic acid treatment (p &lt; 0.05, q &lt; 0.05), where the majority of altered metabolites belonged to lipid (especially fatty acid metabolism) and amino acid pathways, including several carnitines. These metabolomic effects, and especially the effects on lipid metabolism, may be important for the antileukemic and epigenetic effects of this treatment.<\/jats:p>","DOI":"10.3390\/cells8101229","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T03:07:11Z","timestamp":1570763231000},"page":"1229","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy"],"prefix":"10.3390","volume":"8","author":[{"given":"Ida Sofie","family":"Gr\u00f8nnings\u00e6ter","sequence":"first","affiliation":[{"name":"Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway"},{"name":"Section for Hematology, Institute of Clinical Science, University of Bergen, 5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne Kristin","family":"Fredly","sequence":"additional","affiliation":[{"name":"Department of Medicine, B\u00e6rum Hospital, 1346 B\u00e6rum, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn Tore","family":"Gjertsen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway"},{"name":"Section for Hematology, Institute of Clinical Science, University of Bergen, 5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley Joanne","family":"Hatfield","sequence":"additional","affiliation":[{"name":"Section for Hematology, Institute of Clinical Science, University of Bergen, 5021 Bergen, Norway"},{"name":"Department of Immunology and Transfusion Medicine, Haukeland University Hospital, 5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Bruserud","sequence":"additional","affiliation":[{"name":"Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway"},{"name":"Section for Hematology, Institute of Clinical Science, University of Bergen, 5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.critrevonc.2004.10.012","article-title":"The molecular pathogenesis of acute myeloid leukemia","volume":"56","author":"Steffen","year":"2005","journal-title":"Crit. Rev. Oncol. Hemat."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"ref_3","first-page":"231","article-title":"De-novo acute myeloid-leukemia in patients over 55-years-old - a population-based study of incidence, treatment and outcome","volume":"9","author":"Taylor","year":"1995","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2006.06476.x","article-title":"The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia","volume":"136","author":"Giles","year":"2007","journal-title":"Brit. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdj112","article-title":"Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: The dark side of the moon","volume":"17","author":"Latagliata","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Delcuve, G.P., Khan, D.H., and Davie, J.R. (2012). Roles of histone deacetylases in epigenetic regulation: Emerging paradigms from studies with inhibitors. Clin. Epigenetics, 4.","DOI":"10.1186\/1868-7083-4-5"},{"key":"ref_10","first-page":"14934","article-title":"Cancer epigenetics: Mechanisms and crosstalk of a HDAC inhibitor, vorinostat","volume":"2","author":"Lee","year":"2013","journal-title":"Chemotherapy"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/leu.2010.276","article-title":"Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia","volume":"25","author":"Santos","year":"2011","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.leukres.2010.11.006","article-title":"Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival","volume":"35","author":"Tickenbrock","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"Gottlicher","year":"2001","journal-title":"Embo. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8903","DOI":"10.1158\/0008-5472.CAN-05-2726","article-title":"Sequential valproic acid\/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia","volume":"66","author":"Cimino","year":"2006","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/leu.2012.39","article-title":"Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL","volume":"26","author":"Leiva","year":"2012","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1124\/jpet.106.118406","article-title":"Targeting AML1\/ETO-histone deacetylase repressor complex: A novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1\/ETO-positive acute myeloid leukemia cells","volume":"321","author":"Liu","year":"2007","journal-title":"J. Pharm. Exp."},{"key":"ref_17","first-page":"1529","article-title":"Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors","volume":"31","author":"Stapnes","year":"2007","journal-title":"Int. J. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00432-019-02931-1","article-title":"Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia","volume":"145","author":"Forthun","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Fredly, H., Ersvaer, E., Kittang, A.O., Tsykunova, G., Gjertsen, B.T., and Bruserud, O. (2013). The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clin. Epigenetics, 5.","DOI":"10.1186\/1868-7083-5-13"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Fredly, H., Gjertsen, B.T., and Bruserud, O. (2013). Histone deacetylase inhibition in the treatment of acute myeloid leukemia: The effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin. Epigenetics, 5.","DOI":"10.1186\/1868-7083-5-12"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","article-title":"Acute promyelocytic leukemia: From highly fatal to highly curable","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/157339409789712645","article-title":"The combination of conventional chemotherapy with new targeted therapy in hematologic malignancies: The safety and efficiency of low- dose cytarabine supports its combination with new therapeutic agents in early clinical trials","volume":"5","author":"Fredly","year":"2009","journal-title":"Curr. Cancer Ther. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood.V99.6.2199","article-title":"Retinoic acid-induced cell cycle arrest of human myeloid cell lines is associated with sequential down-regulation of c-Myc and cyclin E and posttranscriptional up-regulation of p27(Kip1)","volume":"99","author":"Dimberg","year":"2002","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.blre.2015.01.002","article-title":"An ATRActive future for differentiation therapy in AML","volume":"29","author":"Johnson","year":"2015","journal-title":"Blood Rev."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Forthun, R.B., SenGupta, T., Skjeldam, H.K., Lindvall, J.M., McCormack, E., Gjertsen, B.T., and Nilsen, H. (2012). Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLoS ONE.","DOI":"10.1371\/journal.pone.0048992"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/ajh.23116","article-title":"Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment","volume":"87","author":"Fredly","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.leukres.2008.10.005","article-title":"A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid","volume":"33","author":"Ryningen","year":"2009","journal-title":"Leuk Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood-2014-02-554204","article-title":"A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Nepstad, I., Reikvam, H., Brenner, A.K., Bruserud, O., and Hatfield, K.J. (2018). Resistance to the antiproliferative in vitro effect of PI3K-Akt-mTOR inhibition in primary human acute myeloid leukemia cells is associated with altered cell metabolism. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020382"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000488422","article-title":"Retinoic acid increases fatty acid oxidation and irisin expression in skeletal muscle cells and impacts irisin in vivo","volume":"46","author":"Amengual","year":"2018","journal-title":"Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/15563650902752376","article-title":"Carnitine in the treatment of valproic acid-induced toxicity","volume":"47","author":"Lheureux","year":"2009","journal-title":"Clin. Toxicol. (Phila. Pa.)"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1016\/j.febslet.2008.08.028","article-title":"Pyruvate uptake is inhibited by valproic acid and metabolites in mitochondrial membranes","volume":"582","author":"Aires","year":"2008","journal-title":"Febs. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/0006-2952(92)90324-C","article-title":"In vitro effects of valproate and valproate metabolites on mitochondrial oxidations: Relevance of CoA sequestration to the observed inhibitions","volume":"43","author":"Ponchaut","year":"1992","journal-title":"Biochem. Pharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review","volume":"31","author":"Silva","year":"2008","journal-title":"J. Inherit. Metab Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0009-2797(01)00234-4","article-title":"Differential effect of valproate and its \u03942- and \u03944-unsaturated metabolites, on the \u03b2-oxidation rate of long-chain and medium-chain fatty acids","volume":"137","author":"Silva","year":"2001","journal-title":"Chem. -Biol. Interact."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0009-9120(01)00272-7","article-title":"Characterization of plasma acylcarnitines in patients under valproate monotherapy using ESI-MS\/MS","volume":"34","author":"Silva","year":"2001","journal-title":"Clin. Biochem."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ribot, J., Arreguin, A., Kuda, O., Kopecky, J., Palou, A., and Bonet, M.L. (2019). Novel markers of the metabolic impact of exogenous retinoic acid with a focus on acylcarnitines and amino acids. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20153640"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00277-016-2810-z","article-title":"All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: Results of the randomized AMLSG 07-04 study","volume":"95","author":"Schlenk","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood.V128.22.589.589","article-title":"Results of the randomized phase II study decider (AMLSG 14-09) comparing decitabine (DAC) with or without valproic acid (VPA) and with or without all-trans retinoic acid (ATRA) add-on in newly diagnosed elderly non-fit AML patients","volume":"128","author":"Grishina","year":"2016","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2014-11-611459","article-title":"Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells","volume":"125","author":"Martelli","year":"2015","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/blood-2015-05-646786","article-title":"All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3\/ITD+ leukemia stem cells in vitro and in vivo","volume":"127","author":"Ma","year":"2016","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1084\/jem.20150736","article-title":"Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia","volume":"213","author":"Boutzen","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1182\/blood-2013-12-546283","article-title":"Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients","volume":"123","author":"Tassara","year":"2014","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11001","DOI":"10.1007\/s13277-016-4985-2","article-title":"Valproic acid may exerts its cytotoxic effect through rassf1a expression induction in acute myeloid leukemia","volume":"37","author":"Davood","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41375-018-0293-8","article-title":"Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: Predominant synergistic gene downregulation associated with gene body demethylation","volume":"33","author":"Schlosser","year":"2019","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.exphem.2017.04.007","article-title":"Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation","volume":"52","author":"Verhagen","year":"2017","journal-title":"Exp. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/15592294.2016.1187350","article-title":"Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks","volume":"11","author":"Rucker","year":"2016","journal-title":"Epigenetics"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Kreitz, J., Schonfeld, C., Seibert, M., Stolp, V., Alshamleh, I., Oellerich, T., Steffen, B., Schwalbe, H., Schnutgen, F., and Kurrle, N. (2019). Metabolic plasticity of acute myeloid leukemia. Cells, 8.","DOI":"10.3390\/cells8080805"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Castro, I., Sampaio-Marques, B., and Ludovico, P. (2019). Targeting metabolic reprogramming in acute myeloid leukemia. Cells, 8.","DOI":"10.3390\/cells8090967"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood.V98.6.1985","article-title":"Myelodysplastic syndromes standardized response criteria: Further definition","volume":"98","author":"Cheson","year":"2001","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"ref_53","first-page":"132","article-title":"High resolution mass spectrometry improves data quantity and quality as compared to unit mass resolution mass spectrometry in high-throughput profiling metabolomics","volume":"4","author":"Evans","year":"2014","journal-title":"Metabolomics"},{"key":"ref_54","first-page":"56","article-title":"Sphingolipids in mitochondria","volume":"1862","author":"Salama","year":"2017","journal-title":"Biochim. Et Biophys. Acta. Mol. Cell Biol. Lipids"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrc.2017.96","article-title":"Sphingolipid metabolism in cancer signalling and therapy","volume":"18","author":"Ogretmen","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1042\/BJ20111626","article-title":"Ceramide synthases at the centre of sphingolipid metabolism and biology","volume":"441","author":"Mullen","year":"2012","journal-title":"Biochem. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1742-4658.2010.07947.x","article-title":"Fatty acid omega-oxidation as a rescue pathway for fatty acid oxidation disorders in humans","volume":"278","author":"Wanders","year":"2011","journal-title":"Febs J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fgene.2018.00405","article-title":"Epigenetic-transcriptional regulation of fatty acid metabolism and its alterations in leukaemia","volume":"9","author":"Maher","year":"2018","journal-title":"Front. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/leu.2017.307","article-title":"A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target","volume":"32","author":"Yan","year":"2018","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"9440","DOI":"10.1073\/pnas.1530509100","article-title":"Statistical significance for genomewide studies","volume":"100","author":"Storey","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"key":"ref_62","first-page":"1513","article-title":"Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: Problems and approaches. 2006, 91, 1513\u20131522","volume":"91","author":"Deschler","year":"2006","journal-title":"Haematologica"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archinte.162.14.1597","article-title":"The outcomes and costs of acute myeloid leukemia among the elderly","volume":"162","author":"Menzin","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00726-016-2215-2","article-title":"Amino acid profiling as a method of discovering biomarkers for early diagnosis of cancer","volume":"48","author":"Siminska","year":"2016","journal-title":"Amino Acids"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.mam.2016.11.010","article-title":"Folate status and colorectal cancer risk: A 2016 update","volume":"53","author":"Mason","year":"2017","journal-title":"Mol. Asp. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2147\/PPA.S87069","article-title":"Analysis of the characteristics and prognosis of advanced non-small-cell lung cancer in older patients","volume":"9","author":"Gao","year":"2015","journal-title":"Patient Prefer. Adher."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Gu, Y., Chen, T.X., Fu, S.Z., Sun, X., Wang, L.Y., Wang, J., Lu, Y.F., Ding, S.M., Ruan, G.D., and Teng, L.S. (2015). Perioperative dynamics and significance of amino acid profiles in patients with cancer. J. Transl. Med., 13.","DOI":"10.1186\/s12967-015-0408-1"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: Understanding the molecular basis","volume":"14","author":"Argiles","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10495-015-1137-x","article-title":"Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells","volume":"20","author":"Wu","year":"2015","journal-title":"Apoptosis"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/leu.2014.10","article-title":"A role for oleoylethanolamide in chronic lymphocytic leukemia","volume":"28","author":"Masoodi","year":"2014","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"27849","DOI":"10.1074\/jbc.M404087200","article-title":"Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha)","volume":"279","author":"Guzman","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1093\/jn\/133.12.4083","article-title":"Conjugated linoleic acids lower the release of eicosanoids and nitric oxide from human aortic endothelial cells","volume":"133","author":"Eder","year":"2003","journal-title":"J. Nutr."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nrc1411","article-title":"Biologically active sphingolipids in cancer pathogenesis and treatment","volume":"4","author":"Ogretmen","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1182\/blood-2007-10-113068","article-title":"Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias","volume":"111","author":"Kim","year":"2008","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0163-7827(01)00003-0","article-title":"Plasmalogens: Biosynthesis and functions","volume":"40","author":"Nagan","year":"2001","journal-title":"Prog. Lipid Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbamem.2003.08.001","article-title":"Plasmalogens protect unsaturated lipids against UV-induced oxidation in monolayer","volume":"1616","author":"Morandat","year":"2003","journal-title":"Biochim. Et Biophys. Acta (Bba) - Biomembr."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1093\/jn\/133.12.4090","article-title":"All-trans-retinoic acid rapidly induces glycine N-methyltransferase in a dose-dependent manner and reduces circulating methionine and homocysteine levels in rats","volume":"133","author":"Ozias","year":"2003","journal-title":"J. Nutr."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1189\/jlb.6AB0914-416R","article-title":"Vitamin A induces inhibitory histone methylation modifications and down-regulates trained immunity in human monocytes","volume":"98","author":"Arts","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"ref_79","first-page":"4715","article-title":"DNA methylation in ATRA-treated leukemia cell lines lacking a PML\u2013RAR chromosome translocation","volume":"32","author":"Miftakhova","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/leu.2016.349","article-title":"Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells","volume":"31","author":"Yan","year":"2017","journal-title":"Leukemia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/MCO.0000000000000381","article-title":"Emerging roles of lipid metabolism in cancer progression","volume":"20","author":"Corbet","year":"2017","journal-title":"Curr. Opin. Clin. Nutr."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.molcel.2016.08.014","article-title":"PHD3 loss in cancer enables metabolic reliance on fatty acid oxidation via deactivation of ACC2","volume":"63","author":"German","year":"2016","journal-title":"Mol. Cell."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/10\/1229\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:29:03Z","timestamp":1760189343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/10\/1229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":82,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["cells8101229"],"URL":"https:\/\/doi.org\/10.3390\/cells8101229","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,10]]}}}